reports
- Hilde Van Boxstael
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Wim Lewi
- Lynn Hautekeete
Nextensa Refinancing risks mitigated, cut to hold on SP performance
Nextensa announced the €35.95m disposal of its Gewerbepark Stadlau retail park in Vienna. Since the Bel Tower/Proximus announcement in early 2025, the company has accelerated its disposal program to address upcoming debt maturities (average term 2.6y) and ongoing capex commitments. Refinancing risks now appear largely mitigated. We expect FY25 results to come in ahead of our previous estimates, primarily driven by the strong share price performance of the nowdivested Retail Estates stake. On a r...
- Francesca Ferragina
- Michiel Vereycken
Real Estate Update/A new normality
European real estate rebounded in 2025, signalling positive momentum after two difficult years. In 2026, we expect investors to adapt to a new, normalised environment with recalibrated profitability that should drive transaction activity. This comes alongside a normalisation of rents (on the back of lower inflation) – a slowdown that will be notable but largely expected. We see a company's ability (and willingness) to pursue EPS-accretive investments and being active in capital recycling opportu...
WHA WERELDHAVE N.V.
VNA VONOVIA SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
RET RETAIL ESTATES NV
VASTB VASTNED RETAIL BELGIUM NV
MONT MONTEA SCA
AED AEDIFICA SA
ASC ASCENCIO SCA
VGP VGP NV
NSI NSI N.V.
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
19XX NEPI ROCKCASTLE N.V.
Nextensa sells retail park in Vienna to Union Investment
Nextensa sells retail park in Vienna to Union Investment NON-REGULATED INFORMATIONBrussels, 14 January 2026, 17:55 Nextensa sells retail park in Vienna to Union Investment Nextensa announces the sale of its retail park Gewerbepark Stadlau in Vienna to an open-ended special real estate fund managed by Union Investment. The retail park, located in Donaustadt, Vienna's 22nd district, was originally built in 1996 as a DIY store. In 2016, it underwent extensive restructuring as a retail park and was expanded by around 3,000 m². The asset comprises a lettable area of nearly 11,000 m² and is ...
Nextensa vend centre commercial à Vienne à Union Investment
Nextensa vend centre commercial à Vienne à Union Investment INFORMATION NON-RÉGLEMENTÉEBruxelles, 14 janvier 2026, 17h55 Nextensa vend centre commercial à Vienne à Union Investment Nextensa annonce la vente de son centre commercial Gewerbepark Stadlau à Vienne à un fonds immobilier spécial ouvert géré par Union Investment. Situé dans le 22e arrondissement de Vienne, Donaustadt, ce centre commercial a été construit en 1996 pour accueillir un magasin de bricolage. En 2016, il a fait l'objet d'une restructuration complète pour devenir un parc commercial et a été agrandi d'environ 3 000 m². ...
Nextensa verkoopt retailpark in Wenen aan Union Investment
Nextensa verkoopt retailpark in Wenen aan Union Investment NIET-GEREGLEMENTEERDE INFORMATIEBrussel, 14 januari 2026, 17u55 Nextensa verkoopt retailpark in Wenen aan Union Investment Nextensa kondigt de verkoop aan van zijn retailpark Gewerbepark Stadlau in Wenen aan een open-ended gespecialiseerd vastgoedfonds, beheerd door Union Investment. Het retailpark, gelegen in Donaustadt, het 22e district van Wenen, werd oorspronkelijk in 1996 gebouwd als doe-het-zelfzaak. In 2016 onderging het een ingrijpende omvorming tot retailpark en werd het met ongeveer 3.000 m² uitgebreid. Het pand he...
- Hilde Van Boxstael
- Wim Lewi
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Confere...
Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference Daix (France), New York City (New York, United States), December 17, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to present a corporate overview, and will engage with Inventiva’s leadership team in investor meetings, at the upcoming 44th Annual J.P. Morgan Healthcare Co...
Inventiva présentera à la 44e conférence annuelle J.P. Morgan Healthca...
Inventiva présentera à la 44e conférence annuelle J.P. Morgan Healthcare Daix (France), New York City (New York, États-Unis), le 17 décembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son Directeur général, Andrew Obenshain, a été invité à présenter une vue d’ensemble de la Société et qu’il participera, aux côtés de l’équipe de direction d’Inventi...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
- Jacob Mekhael
- Thibault Leneeuw
- Jacob Mekhael
MaaT Pharma Final Xervyteg phase 3 data confirm strong survival outcom...
MaaT reported the final results from the phase 3 (ARES) trial of Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD at the American Society of Hematology (ASH) conference, being held 6-9 December 2025. The final OS results from the phase 3 (ARES) trial of MaaT013 coming in at 54% at 1 year confirm the previously reported 54% probability of survival that was shared with the topline readout in January 2025. We believe this brings a significant benefit vs. the 15% 1-year OS reported...
Results of the Votes of the Combined Shareholders’ General Meeting of...
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025 Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Thursday November 27, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Pasteur,...
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réu...
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 27 novembre 2025 Daix (France), New York City (New York, Etats-Unis), le 28 novembre 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce les résultats des votes de son Assemblée Générale Mixte. L’Assemblée Générale Mixte s’est tenue le jeudi 27 novembre 2025 à 9 heures à l'Hôtel Villa M – 24-30 Bd P...
Information relating to the stabilization activities carried out in th...
Information relating to the stabilization activities carried out in the context of its recent offering Daix (France), New York City (New York, United States), November 24, 2025 – Publication of information relating to the stabilization activities carried out in the context of the recent public offering of Inventiva (the "Company" or "Inventiva") in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01. As announced on 18 November 2025, the underwriters have exercised in full the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.